Premium
The efficacy of an aromatic retinoid, Tigason (etretinate), in the treatment of Darier's disease
Author(s) -
BURGE S.M.,
WILKINSON J.D.,
MILLER A.J.,
RYAN T.J.
Publication year - 1981
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/j.1365-2133.1981.tb00754.x
Subject(s) - etretinate , darier's disease , medicine , adverse effect , dermatology , retinoid , darier disease , disease , acitretin , gastroenterology , chemistry , retinoic acid , psoriasis , biochemistry , gene
SUMMARY Eighteen patients with Darier's disease were treated for at least 3 months with the oral aromatic retinoid Tigason (etretinate, Ro 10‐9359). Seventeen of the 18 patients improved but adverse effects were seen in all patients, and were particularly severe in 6. No haematological or biochemical abnormalities were detected during treatment. We conclude that Tigason is an important advance in the treatment of Darier's disease but adverse effects restrict its use in some patients.